Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study

David Mischoulon, Richard C. Shelton, Lee Baer, William V Bobo, Laura Curren, Maurizio Fava, George I. Papakostas

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram. Methods: A multicenter, parallel, randomized, doubleblind, placebo-controlled trial was conducted at 3 US academic medical centers from July 2008 to October 2013. Recruited were 139 outpatients with persistent DSM-IV MDD following an 8-week open-label trial of escitalopram. Subjects were then randomized to adjunctive ziprasidone (escitalopram + ziprasidone, n = 71) or placebo (escitalopram + placebo, n = 68) for 8 additional weeks. Cardiac and metabolic measures were obtained at each treatment visit. Barnes Akathisia Scale and Abnormal Involuntary Movement Scale (AIMS) scores were also obtained. Changes in outcome measures for each treatment group were compared by independent-samples t test. Results: A trend toward significance (P = .06) in corrected QT interval (QTc) increase was observed for ziprasidone (mean [SD] = 8.8 [20.2] milliseconds) versus placebo (-0.02 [25.5] milliseconds). Ziprasidone-treated patients had a significantly greater increase in global akathisia scores (P = .01) and significant weight increase (mean [SD] = 3.5 [11.8] kg, or 7.7 [26.1] lb) compared to placebo (1.0 [6.4] kg, or 2.2 [14.1] lb) (P = .03). No significant changes in AIMS scores were observed for either treatment group. Conclusions: Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo. The effect of ziprasidone on QTc showed a trend toward significance, and therefore caution should be used in the administration of ziprasidone. While ziprasidone augmentation in patients with MDD appears safe, precautions should be taken in practice, specifically regular monitoring of electrocardiogram, weight, extrapyramidal symptoms, and involuntary movements.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalJournal of Clinical Psychiatry
Volume78
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Citalopram
Major Depressive Disorder
Placebos
Psychomotor Agitation
ziprasidone
Weights and Measures
Dyskinesias
Diagnostic and Statistical Manual of Mental Disorders
Weight Gain
Electrocardiography
Outpatients
Therapeutics
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Ziprasidone augmentation of escitalopram for major depressive disorder : Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study. / Mischoulon, David; Shelton, Richard C.; Baer, Lee; Bobo, William V; Curren, Laura; Fava, Maurizio; Papakostas, George I.

In: Journal of Clinical Psychiatry, Vol. 78, No. 4, 01.04.2017, p. 449-455.

Research output: Contribution to journalArticle

Mischoulon, David ; Shelton, Richard C. ; Baer, Lee ; Bobo, William V ; Curren, Laura ; Fava, Maurizio ; Papakostas, George I. / Ziprasidone augmentation of escitalopram for major depressive disorder : Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study. In: Journal of Clinical Psychiatry. 2017 ; Vol. 78, No. 4. pp. 449-455.
@article{8b8cef3b60bc49cea87f8933adb18d30,
title = "Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study",
abstract = "Objective: To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram. Methods: A multicenter, parallel, randomized, doubleblind, placebo-controlled trial was conducted at 3 US academic medical centers from July 2008 to October 2013. Recruited were 139 outpatients with persistent DSM-IV MDD following an 8-week open-label trial of escitalopram. Subjects were then randomized to adjunctive ziprasidone (escitalopram + ziprasidone, n = 71) or placebo (escitalopram + placebo, n = 68) for 8 additional weeks. Cardiac and metabolic measures were obtained at each treatment visit. Barnes Akathisia Scale and Abnormal Involuntary Movement Scale (AIMS) scores were also obtained. Changes in outcome measures for each treatment group were compared by independent-samples t test. Results: A trend toward significance (P = .06) in corrected QT interval (QTc) increase was observed for ziprasidone (mean [SD] = 8.8 [20.2] milliseconds) versus placebo (-0.02 [25.5] milliseconds). Ziprasidone-treated patients had a significantly greater increase in global akathisia scores (P = .01) and significant weight increase (mean [SD] = 3.5 [11.8] kg, or 7.7 [26.1] lb) compared to placebo (1.0 [6.4] kg, or 2.2 [14.1] lb) (P = .03). No significant changes in AIMS scores were observed for either treatment group. Conclusions: Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo. The effect of ziprasidone on QTc showed a trend toward significance, and therefore caution should be used in the administration of ziprasidone. While ziprasidone augmentation in patients with MDD appears safe, precautions should be taken in practice, specifically regular monitoring of electrocardiogram, weight, extrapyramidal symptoms, and involuntary movements.",
author = "David Mischoulon and Shelton, {Richard C.} and Lee Baer and Bobo, {William V} and Laura Curren and Maurizio Fava and Papakostas, {George I.}",
year = "2017",
month = "4",
day = "1",
doi = "10.4088/JCP.15m10426",
language = "English (US)",
volume = "78",
pages = "449--455",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Ziprasidone augmentation of escitalopram for major depressive disorder

T2 - Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study

AU - Mischoulon, David

AU - Shelton, Richard C.

AU - Baer, Lee

AU - Bobo, William V

AU - Curren, Laura

AU - Fava, Maurizio

AU - Papakostas, George I.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective: To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram. Methods: A multicenter, parallel, randomized, doubleblind, placebo-controlled trial was conducted at 3 US academic medical centers from July 2008 to October 2013. Recruited were 139 outpatients with persistent DSM-IV MDD following an 8-week open-label trial of escitalopram. Subjects were then randomized to adjunctive ziprasidone (escitalopram + ziprasidone, n = 71) or placebo (escitalopram + placebo, n = 68) for 8 additional weeks. Cardiac and metabolic measures were obtained at each treatment visit. Barnes Akathisia Scale and Abnormal Involuntary Movement Scale (AIMS) scores were also obtained. Changes in outcome measures for each treatment group were compared by independent-samples t test. Results: A trend toward significance (P = .06) in corrected QT interval (QTc) increase was observed for ziprasidone (mean [SD] = 8.8 [20.2] milliseconds) versus placebo (-0.02 [25.5] milliseconds). Ziprasidone-treated patients had a significantly greater increase in global akathisia scores (P = .01) and significant weight increase (mean [SD] = 3.5 [11.8] kg, or 7.7 [26.1] lb) compared to placebo (1.0 [6.4] kg, or 2.2 [14.1] lb) (P = .03). No significant changes in AIMS scores were observed for either treatment group. Conclusions: Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo. The effect of ziprasidone on QTc showed a trend toward significance, and therefore caution should be used in the administration of ziprasidone. While ziprasidone augmentation in patients with MDD appears safe, precautions should be taken in practice, specifically regular monitoring of electrocardiogram, weight, extrapyramidal symptoms, and involuntary movements.

AB - Objective: To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram. Methods: A multicenter, parallel, randomized, doubleblind, placebo-controlled trial was conducted at 3 US academic medical centers from July 2008 to October 2013. Recruited were 139 outpatients with persistent DSM-IV MDD following an 8-week open-label trial of escitalopram. Subjects were then randomized to adjunctive ziprasidone (escitalopram + ziprasidone, n = 71) or placebo (escitalopram + placebo, n = 68) for 8 additional weeks. Cardiac and metabolic measures were obtained at each treatment visit. Barnes Akathisia Scale and Abnormal Involuntary Movement Scale (AIMS) scores were also obtained. Changes in outcome measures for each treatment group were compared by independent-samples t test. Results: A trend toward significance (P = .06) in corrected QT interval (QTc) increase was observed for ziprasidone (mean [SD] = 8.8 [20.2] milliseconds) versus placebo (-0.02 [25.5] milliseconds). Ziprasidone-treated patients had a significantly greater increase in global akathisia scores (P = .01) and significant weight increase (mean [SD] = 3.5 [11.8] kg, or 7.7 [26.1] lb) compared to placebo (1.0 [6.4] kg, or 2.2 [14.1] lb) (P = .03). No significant changes in AIMS scores were observed for either treatment group. Conclusions: Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo. The effect of ziprasidone on QTc showed a trend toward significance, and therefore caution should be used in the administration of ziprasidone. While ziprasidone augmentation in patients with MDD appears safe, precautions should be taken in practice, specifically regular monitoring of electrocardiogram, weight, extrapyramidal symptoms, and involuntary movements.

UR - http://www.scopus.com/inward/record.url?scp=85018455166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018455166&partnerID=8YFLogxK

U2 - 10.4088/JCP.15m10426

DO - 10.4088/JCP.15m10426

M3 - Article

C2 - 27835715

AN - SCOPUS:85018455166

VL - 78

SP - 449

EP - 455

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -